Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin

Michel Afargan*, Eva Tiensuu Janson, Garry Gelerman, Rakefet Rosenfeld, Offer Ziv, Olga Karpov, Amnon Wolf, Moshe Bracha, Dvira Shohat, George Liapakis, Chaim Gilon, Amnon Hoffman, David Stephensky, Kjell Oberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

Somatostatin, also known as somatotropin release-inhibiting factor (SRIF), is a natural cyclic peptide inhibitor of pituitary, pancreatic, and gastrointestinal secretion. Its long-acting analogs are in clinical use for treatment of various endocrine syndromes and gastrointestinal anomalies. These analogs are more potent inhibitors of the endocrine release of GH, glucagon, and insulin than the native SRIF; hence, they do not display considerable physiological selectivity. Our goal was to design effective and physiologically selective SRIF analogs with potential therapeutic value. We employed an integrated approach consisting of screening of backbone cyclic peptide libraries constructed on the basis of molecular modeling of known SRIF agonists and of high throughput receptor binding assays with each of the five cloned human SRIF receptors (hsst1-5). By using this approach, we identified a novel, high affinity, enzymatically stable, and long-acting SRIF analog, PTR-3173, which binds with nanomolar affinity to human SRIF receptors hsst2, hsst4, and hsst5. The hsst5 and the rat sst5 (rsst5) forms have the same nanomolar affinity for this analog. In the human carcinoid-derived cell line BON-1, PTR-3173 inhibits forskolin-stimulated cAMP accumulation as efficiently as the drug octreotide, indicating its agonistic effect in this human cell system. In hormone secretion studies with rats, we found that PTR-3173 is 1000-fold and more than 10,000-fold more potent in inhibiting GH release than glucagon and insulin release, respectively. These results suggest that PTR-3173 is the first highly selective somatostatinergic analog for the in vivo inhibition of GH secretion, with minimal or no effect on glucagon and insulin release, respectively.

Original languageAmerican English
Pages (from-to)477-486
Number of pages10
JournalEndocrinology
Volume142
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Dive into the research topics of 'Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin'. Together they form a unique fingerprint.

Cite this